Description of Collaborative Activity: |
This Memorandum of Understanding (MOU), signed in 2007 and renewed in 2012, establishes an official relationship in clinical proteomic regulatory science between the National Cancer Institute's (NCI) Office of Cancer Clinical Proteomics Research and the Food and Drug Administration (FDA). Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development. |
